# Carl H. June

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/carl-h-june/

## Facts

| Field | Value |
| --- | --- |
| Citations | 149,600 |
| Field | CAR-T cell therapy research |
| h-index | 179 |
| i10-index | 656 |
| Last Known Institution | Hospital of the University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5008558372 |
| ORCID iD | https://orcid.org/0000-0003-0241-3557 |
| Works | 1,423 |

## Researcher papers

- [Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia](https://scholariq.org/papers/tisagenlecleucel-in-children-and-young-adults-with-b-cell-lymphoblastic-leukemia/)
- [NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma](https://scholariq.org/papers/ny-eso-1-specific-tcr-engineered-t-cells-mediate-sustained-antigen-specific/)
- [B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma](https://scholariq.org/papers/b-cell-maturation-antigen-specific-car-t-cells-are-clinically-active-in-multiple/)
- [CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.](https://scholariq.org/papers/cd28-activation-pathway-regulates-the-production-of-multiple-t-cell-derived/)
- [Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma](https://scholariq.org/papers/chimeric-antigen-receptor-t-cells-against-cd19-for-multiple-myeloma/)
- [Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells](https://scholariq.org/papers/mitigation-of-chromosome-loss-in-clinical-crispr-cas9-engineered-t-cells/)
- [Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation](https://scholariq.org/papers/adoptive-transfer-of-costimulated-t-cells-induces-lymphocytosis-in-patients-with/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Virus-based gene therapy research](https://scholariq.org/topics/virus-based-gene-therapy-research-2/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

## Researcher university

- [Hospital of the University of Pennsylvania](https://scholariq.org/institutions/hospital-of-the-university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.